Abstract
Promise of new translational safety biomarkers in drug development and some challenges to regulatory qualification
Author(s): Frank D Sistare, Joseph J DeGeorgeOne promise of new translational safety biomarkers (TSBs) is their ability to demonstrate that toxicities in animal studies are monitorable at an early stage, such that human relevance of potential adverse effects of drugs can be safely and definitively evaluated in clinical trials.